Johnson Matthey’s global Catalysis and Chiral Technologies (JMCCT) business unit is expanding its existing specialty ligand manufacturing capability to include commercial-scale manufacturing up to 100 kilograms. This expansion is largely focused on the Buchwald ligands from the Massachusetts Institute of Technology for customers throughout Europe, Asia and the United States.
The Buchwald ligands offered by JMCCT are a class of bulky and electron-rich dialkylbiaryl monophosphine ligands, which are used for the in situ generation of active catalysts. These ligands are used for coupling reactions in the manufacture of both pharmaceuticals and specialty chemicals and are more commonly offered at a research scale for use in the laboratory.
The expansion will also complement JMCCT initiatives to continually create a stronger global supply chain.
For more information, visit www.jmcct.com.
